Targeting the Brain’s Immune System in Alzheimer’s Disease

Episode Summary

Executive Summary: The conversation centers on Avenco Therapeutics’ strategy to treat Alzheimer’s by targeting neuroinflammation with natural killer cell-derived extracellular vesicles (NKEVs). Alan Trownson argues that Alzheimer’s is too complex for single-target drugs and that modulating microglia and the brain’s immune environment may better address amyloid, tau, and cognitive decline, with potential use in combination therapies and broader neurological diseases.

Main Topics: Alzheimer’s as a multifactorial disease (Priority: 5/5): Trownson argues that Alzheimer’s is not adequately addressed by targeting amyloid or tau alone because inflammation, immune dysfunction, plaque buildup, and neurodegeneration are interconnected. Inflammation and microglia as central therapeutic targets (Priority: 5/5): He frames neuroinflammation as a likely initiating and sustaining force in Alzheimer’s progression and emphasizes microglia as key brain immune cells that need to be restored to normal function. Natural killer cell-derived extracellular vesicles (NKEVs) (Priority: 5/5): Avenco is developing nanoscale vesicles from NK cells that carry proteins and microRNAs, with the goal of crossing the blood-brain barrier and modulating brain immunity. Mechanism and preclinical effects of NKEVs (Priority: 4/5): The vesicles reportedly stimulate microglia to clear amyloid, reduce inflammatory markers in microglia and astrocytes, and may affect tau phosphorylation; they appear more effective than EVs from other cell sources in this context. Delivery, manufacturability, and scalability (Priority: 4/5): Trownson highlights nasal or IV delivery, room-temperature stability via freeze-drying, and large-scale NK-cell manufacturing as advantages over cell therapies. Combination therapy and clinical translation (Priority: 4/5): He sees NKEVs as a foundation for combination regimens with antibodies or small molecules, and believes biomarkers will be essential for proving biological and cognitive benefit in trials. Broader applications and industry/regulatory outlook (Priority: 3/5): Beyond Alzheimer’s, the company is considering traumatic brain injury and Parkinson’s, while Trownson expects EV regulation to be manageable given the growing clinical trial base and low apparent safety risk.

Key Arguments: Alzheimer’s is too complex to be solved by single-target therapies; inflammation and immune dysfunction must be addressed alongside amyloid and tau. Microglia are not functioning properly in Alzheimer’s, and restoring their cleaning and regulatory role may be key to changing disease course. NKEVs may cross the blood-brain barrier more easily than NK cells and could replicate beneficial effects seen in NK-cell clinical experiences. Avenco’s NKEVs can stimulate amyloid clearance, suppress inflammatory signaling, and potentially influence tau pathology, making them a platform for combination therapy. Nasal delivery and freeze-dried formulation could make EV therapy simpler, safer, and more scalable than live-cell therapies. The field is moving toward biologically complex and immune-based approaches because inflammation appears to be a fundamental component of neurodegeneration. Biomarkers are essential to show whether treatment affects the disease broadly or only one component, and cognitive endpoints remain clinically important. Regulatory concerns may be modest because EVs have a growing clinical literature and appear less immunogenic than cell therapies.

Data Points: NKEV size: 50 to 150 nanometers - Trownson describes the extracellular vesicles as nanoscale particles that can cross the blood-brain barrier. NKGen reported response: 90-plus percent response - He cites NKGen’s clinical experience in Alzheimer’s patients as a serendipitous source of support for NK-cell-based approaches. TBI economic burden: $1.1 trillion per year - He references a Lancet publication to illustrate the scale of traumatic brain injury as a potential future indication. Large-scale NK-cell manufacturing volume: 200 liters to 500 liters - He says mature NK cells can be expanded at industrial scale to generate many EV doses. Clinical trial landscape for EVs: Several hundred clinical trials - He uses the breadth of ongoing EV trials to argue regulatory risk is likely low.

Pivotal Quotes: "The condition is too complicated to just target single components." — Alan Trownson: Explaining why amyloid- or tau-only strategies have not produced recovery in Alzheimer’s disease. "I think the immunology has been left out." — Alan Trownson: Arguing that neuroinflammation and brain immune dysfunction have been under-addressed in drug development. "If we can show that there's some impact of this type of approach on the brain's immune system, it will change the field, I think, dramatically, as you see as we saw in cancer." — Alan Trownson: Describing the potential of NKEVs to drive a paradigm shift in Alzheimer’s treatment.

Implications: If validated, NKEVs could shift Alzheimer’s care toward immune-modulating combination therapy, improve drug delivery to the brain, and open a scalable platform for other neurodegenerative conditions.